Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel D Joyce

Showing results (31-40 of 52) with videos related to

Pageof 6
Sort By:
The Journal of Urology|July 7, 2023
Coping Mechanisms for Financial Toxicity Among Patients With Metastatic Prostate Cancer: A Survey-based AssessmentDaniel D Joyce, Phillip J Schulte, Eugene D Kwon, et al.
Urology Practice|June 20, 2024
Financial Toxicity Among Patients With Metastatic Prostate Cancer: A Mixed Methods Approach to Identify Effective InterventionsDaniel D Joyce, Kasey R Boehmer, Celia C Kamath, et al.
The Journal of Urology|September 6, 2022
Cost-effectiveness of Adjuvant Pembrolizumab After Nephrectomy for High-risk Renal Cell Carcinoma: Insights for Patient Selection From a Markov ModelVidit Sharma, Kevin M Wymer, Daniel D Joyce, et al.
Urology|November 27, 2022
Perioperative and Oncologic Outcomes Associated with Simultaneous Radical Cystectomy and NephroureterectomyCameron J Britton, Harrison C Gottlich, Robert F Tarrell, et al.
The Journal of Urology|May 18, 2026
<b>Cost-Effectiveness of Immune Checkpoint Inhibitor Therapy plus BCG for High-Risk Non-muscle Invasive Bladder Cancer: Analyses of CREST</b>, <b>POTOMAC, and ALBAN</b>Daniel D Joyce, Vidit Sharma, Grace E Ratcliff, et al.
The Journal of Urology|June 24, 2022
Unplanned Conversion From Partial to Radical Nephrectomy: An Analysis of Incidence, Etiology, and Risk FactorsMatvey Tsivian, Daniel D Joyce, Vignesh T Packiam, et al.
Cancer|October 17, 2022
Comparative cost-effectiveness of neoadjuvant chemotherapy regimens for muscle-invasive bladder cancer: Results according to VESPER dataDaniel D Joyce, Kevin M Wymer, Vidit Sharma, et al.
JAMA Network Open|June 23, 2025
Cost-Effectiveness of Trimodal Therapy and Radical Cystectomy for Muscle-Invasive Bladder CancerDaniel D Joyce, Kevin M Wymer, John A Graves, et al.
Journal of the National Cancer Institute|October 11, 2023
Comparative cost-effectiveness of contemporary treatment strategies for stage IIA seminomaDaniel D Joyce, Vidit Sharma, Kevin M Wymer, et al.
The Journal of Urology|June 20, 2023
The Impact of Metastasis Histopathology on Oncologic Outcomes for Patients With Surgically Resected Metastatic Renal Cell CarcinomaRodrigo Rodrigues Pessoa, Reza Nabavizadeh, Fernando Quevedo, et al.
Pageof 6

Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
The Journal of Urology|July 7, 2023
Coping Mechanisms for Financial Toxicity Among Patients With Metastatic Prostate Cancer: A Survey-based AssessmentDaniel D Joyce, Phillip J Schulte, Eugene D Kwon, et al.
Urology Practice|June 20, 2024
Financial Toxicity Among Patients With Metastatic Prostate Cancer: A Mixed Methods Approach to Identify Effective InterventionsDaniel D Joyce, Kasey R Boehmer, Celia C Kamath, et al.
The Journal of Urology|September 6, 2022
Cost-effectiveness of Adjuvant Pembrolizumab After Nephrectomy for High-risk Renal Cell Carcinoma: Insights for Patient Selection From a Markov ModelVidit Sharma, Kevin M Wymer, Daniel D Joyce, et al.
Urology|November 27, 2022
Perioperative and Oncologic Outcomes Associated with Simultaneous Radical Cystectomy and NephroureterectomyCameron J Britton, Harrison C Gottlich, Robert F Tarrell, et al.
The Journal of Urology|May 18, 2026
<b>Cost-Effectiveness of Immune Checkpoint Inhibitor Therapy plus BCG for High-Risk Non-muscle Invasive Bladder Cancer: Analyses of CREST</b>, <b>POTOMAC, and ALBAN</b>Daniel D Joyce, Vidit Sharma, Grace E Ratcliff, et al.
The Journal of Urology|June 24, 2022
Unplanned Conversion From Partial to Radical Nephrectomy: An Analysis of Incidence, Etiology, and Risk FactorsMatvey Tsivian, Daniel D Joyce, Vignesh T Packiam, et al.
Cancer|October 17, 2022
Comparative cost-effectiveness of neoadjuvant chemotherapy regimens for muscle-invasive bladder cancer: Results according to VESPER dataDaniel D Joyce, Kevin M Wymer, Vidit Sharma, et al.
JAMA Network Open|June 23, 2025
Cost-Effectiveness of Trimodal Therapy and Radical Cystectomy for Muscle-Invasive Bladder CancerDaniel D Joyce, Kevin M Wymer, John A Graves, et al.
Journal of the National Cancer Institute|October 11, 2023
Comparative cost-effectiveness of contemporary treatment strategies for stage IIA seminomaDaniel D Joyce, Vidit Sharma, Kevin M Wymer, et al.
The Journal of Urology|June 20, 2023
The Impact of Metastasis Histopathology on Oncologic Outcomes for Patients With Surgically Resected Metastatic Renal Cell CarcinomaRodrigo Rodrigues Pessoa, Reza Nabavizadeh, Fernando Quevedo, et al.
Pageof 6